Defining the optimal dose of stereotactic radiosurgery for treating cerebral metastases in elderly patients

Dirk Rades, Markus Dahlke, Liesa Dziggel, Stefan Janssen, Amira Bajrovic, Ngo Thuy Trang, Mai Trong Khoa, Steven E. Schild

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Background/Aim: In oncology, elderly people are a separate group of patients requiring special consideration. This applies to the treatment of cerebral metastases as well. The present study focused on elderly patients receiving stereotactic radiosurgery (SRS) for few cerebral lesions. Patients and Methods: In 95 patients aged ≥65 years, two SRS doses, 16-18 Gy (n=44) and 20 Gy (n=51), were compared regarding outcomes of SRS. Results: The overall intracerebral control rates at 12 months were 30% after 16- 18 Gy and 45% after 20 Gy (p=0.53). Twelve-month rates of freedom from new intracerebral lesions were 41% and 52%, respectively (p=0.63). Twelve-month local control rates of the irradiated lesions were 55% and 81%, respectively (p=0.069). Overall survival rates at 12 months were 29% and 31%, respectively (p=0.67). Conclusion: SRS with 16- 18 Gy was not significantly inferior to SRS with 20 Gy in elderly patients with few cerebral metastases.

Original languageEnglish (US)
Pages (from-to)5701-5704
Number of pages4
JournalAnticancer Research
Volume35
Issue number10
StatePublished - Oct 1 2015

Keywords

  • Cerebral metastases
  • Elderly patients
  • Optimal dose
  • Stereotactic radiosurgery
  • Treatment results

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Defining the optimal dose of stereotactic radiosurgery for treating cerebral metastases in elderly patients'. Together they form a unique fingerprint.

  • Cite this

    Rades, D., Dahlke, M., Dziggel, L., Janssen, S., Bajrovic, A., Trang, N. T., Khoa, M. T., & Schild, S. E. (2015). Defining the optimal dose of stereotactic radiosurgery for treating cerebral metastases in elderly patients. Anticancer Research, 35(10), 5701-5704.